January 1, 2007Thrombosis and Haemostasis
A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis
Key result
No clinical data is available as the provided text only contains the journal's editorial board and contact information.
Why the study?
Does S18886 reduce platelet deposition in a porcine model of stent-induced thrombosis?
Population
Pigs in an experimental model of stent-induced thrombosis using a Badimon chamber containing a stent…
Comparison
S18886 oral treatment vs Clopidogrel alone, ASA alone, ASA+clopidogrel…
Design
Preclinical
Follow-up
180 minutes
Authors
Discussion
Loading...
Member takes
Implication
May support clinical testing of S18886 in stent thrombosis; leaves open translation from porcine model.
Structured PICO
Does S18886 reduce platelet deposition in a porcine model of stent-induced thrombosis?
P
Population
Pigs in an experimental model of stent-induced thrombosis using a Badimon chamber containing a stent perfused at 212/s
I
Intervention
S18886 (thromboxane A2/prostaglandin H2 receptor antagonist) oral treatment
C
Comparator
Clopidogrel alone, ASA alone, ASA+clopidogrel, and placebo-control
O
Outcome
(111)In-platelet deposition (PD) at 60 and 180 min after drug intakesurrogate
In a porcine model of in-stent thrombosis, S18886 provided potent platelet inhibition comparable to dual antiplatelet therapy but without prolonging bleeding time.
Cite This Study
Vilahur et al. (2007) studied this question. No clinical data is available as the provided text only contains the journal's editorial board and contact information.